Patients should be monitored for evidence of relapse, for disease-related complications, for steroid-related complications and for symptoms that may suggest an alternative diagnosis. In addition to ...

In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those who were randomized to secukinumab were in sustained remission at week 28 compared with 20.3% (95% CI 12.4-30) of those ...

There are several diagnostic challenges in PMR. It is a heterogeneous disease and many features of PMR (pain, stiffness, systemic symptoms and peripheral arthritis ...